Clinical Applications of Somatostatin Receptor (Agonist) PET Tracers beyond Neuroendocrine Tumors

Helgebostad, Rasmus Astrup; Revheim, Mona‐Elisabeth; Johnsrud, Kjersti; Amlie, Kristine; Alavi, Abass; Connelly, Jim

doi:10.3390/diagnostics12020528

Cited by 9 publications

(5 citation statements)

References 86 publications

(92 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Outside the pancreas, an increased uptake of 68 Ga-SSAs has also been reported in inflammatory processes and multiple neoplasms other than NETs. [81,83,95,96]…”

Section: Molecular Imaging Of Pnetsmentioning

confidence: 99%

“…[92][93][94] Outside the pancreas, an increased uptake of 68 Ga-SSAs has also been reported in inflammatory processes and multiple neoplasms other than NETs. [81,83,95,96] Role of 18 F-FDG PET/CT 18 F-FDG has long been the mainstay PET tracer of cancer diagnosis and staging by assessing tumor glucose metabolic activity. However, its use in pNETs remained controversial owing to low uptake in well-differentiated pNETs, especially low-grade well-differentiated pNETs.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Perspective of molecular imaging and peptide receptor radionuclide therapy in pancreatic neuroendocrine tumors: where do we stand?

Zhu

Liu

Huo

2023

Journal of Pancreatology

View full text Add to dashboard Cite

The clinical use of nuclear medicine imaging and therapy in pancreatic neuroendocrine tumors has been greatly strengthened since the approval of 68 Ga-DOTATATE and 177 Lu-DOTATATE. However, many aspects are still under discussion. In this 2-part article, we aim to collect and discuss current evidence of molecular imaging and peptide receptor radionuclide therapy (PRRT) in pancreatic neuroendocrine tumor. In the first part, we will address some critical aspects of 68 Ga-SSAs imaging, including diagnostic efficacy, recurrence detection and follow-up, patient selection for PRRT, and pitfalls in image interpretation. Besides, we will also briefly discuss the role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, special imaging strategy in regard to insulinoma, and the status of radiolabeled somatostatin receptor antagonist. In the second part, we aim to review the current evidence of PRRT in pancreatic neuroendocrine tumor, focusing on efficacy and safety in particular. We will also introduce the recent development of PRRT, including PRRT in high-grade neuroendocrine neoplasms, retreatment PRRT, upfront PRRT, PRRT in the setting of neoadjuvant therapy and conversion therapy, combination therapies with PRRT, PRRT with αradionuclides, and PRRT with antagonists.

show abstract

“…Outside the pancreas, an increased uptake of 68 Ga-SSAs has also been reported in inflammatory processes and multiple neoplasms other than NETs. [81,83,95,96]…”

Section: Molecular Imaging Of Pnetsmentioning

confidence: 99%

mentioning

confidence: 99%

Perspective of molecular imaging and peptide receptor radionuclide therapy in pancreatic neuroendocrine tumors: where do we stand?

Zhu

Liu

Huo

2023

Journal of Pancreatology

View full text Add to dashboard Cite

show abstract

“… 8 Thus, this imaging modality is widely distributed within the clinical routine of nuclear medicine. 9 The 68 Ga-labeled tracers DOTATATE and DOTATOC are the most common clinically applied tracers in patients with meningioma. 7 These tracers provide an improved lesion contrast relative to the background due to a negligible uptake in both osseus structures and the unaffected brain parenchyma.…”

Section: Imaging Of Somatostatin Receptor-expression In Meningiomas U...mentioning

confidence: 99%

Advances in PET imaging for meningioma patients

Galldiks

Albert

Wollring

et al. 2023

Neuro-Oncology Advances

View full text Add to dashboard Cite

In patients with meningioma, diagnosis and treatment planning are predominantly based on anatomical imaging using MRI or CT. Constraints of these imaging modalities include precise meningioma delineation—especially at the skull base, in the case of trans-osseus growth, and in tumors with complex geometry—and the differentiation of post-therapeutic reactive changes from meningioma relapse. Advanced metabolic imaging using PET may help to characterize specific metabolic and cellular features providing additional information beyond the information derived from anatomical imaging alone. Accordingly, the use of PET in meningioma patients is steadily increasing. This review summarizes recent advances in PET imaging helpful for improving the clinical management of patients with meningioma.

show abstract

“…However, SSTR expression is not exclusive to neuroendocrine tumor or meningioma cells. Tracer uptake was also observed by inflammatory pathologies such as cardiovascular disease and ischemia and by various other benign and malignant tumors (21). scRadiotracing has the potential to resolve such inconclusive results by use of back translation in experimental models.…”

Section: Potential Applications Of Scradiotracing In Neurooncology An...mentioning

confidence: 99%

Single-Cell Radiotracer Allocation via Immunomagnetic Sorting to Disentangle PET Signals at Cellular Resolution

et al. 2022

View full text Add to dashboard Cite

With great interest, our independent groups of scientists located in Korea and Germany recognized the use of a very similar methodologic approach to quantify the uptake of radioactive glucose ( 18 F-FDG) at the cellular level. The focus of our investigations was to disentangle microglial 18 F-FDG uptake. To do so, CD11b immunomagnetic cell sorting was applied to isolate microglia cells after in vivo 18 F-FDG injection, to allow simple quantification via a g-counter. Importantly, this technique reveals a snapshot of cellular glucose uptake in living mice at the time of injection since 18 F-FDG is trapped by hexokinase phosphorylation without a further opportunity to be metabolized. Both studies indicated high 18 F-FDG uptake of single CD11b-positive microglia cells and a significant increase in microglial 18 F-FDG uptake when this cell type is activated in the presence of amyloid pathology. Furthermore, another study noticed that immunomagnetic cell sorting after tracer injection facilitated determination of high 18 F-FDG uptake in myeloid cells in a range of tumor models. Here, we aim to discuss the rationale for singlecell radiotracer allocation via immunomagnetic cell sorting (scRadiotracing) by providing examples of promising applications of this innovative technology in neuroscience, oncology, and radiochemistry.

show abstract

Clinical Applications of Somatostatin Receptor (Agonist) PET Tracers beyond Neuroendocrine Tumors

Cited by 9 publications

References 86 publications

Perspective of molecular imaging and peptide receptor radionuclide therapy in pancreatic neuroendocrine tumors: where do we stand?

Perspective of molecular imaging and peptide receptor radionuclide therapy in pancreatic neuroendocrine tumors: where do we stand?

Advances in PET imaging for meningioma patients

Single-Cell Radiotracer Allocation via Immunomagnetic Sorting to Disentangle PET Signals at Cellular Resolution

Contact Info

Product

Resources

About